Extracellular vesicles-miR-205-5p inhibits lymphatic metastasis in pancreatic cancer through diffusely downregulating VEGFA

Quick Facts

  • Publication title: Extracellular vesicles-miR-205-5p inhibits lymphatic metastasis in pancreatic cancer through diffusely downregulating VEGFA
  • Journal: J Cancer
  • Year: 2025
  • DOI: 10.7150/jca.110659
  • PMID/PMCID: 40302796; PMC12036096

Research overview

Through miRNA sequencing of plasma extracellular vesicles (EVs) from PDAC patients, for the first time, we identified that plasma EV-miR-205-5p served as a non-invasive biomarker distinguishing lymphatic metastasis status (N0 vs. The inhibition of early lymph node metastasis, including the lymphangiogenic process, may be a novel strategy for PDAC treatment.

Key findings

Pancreatic ductal adenocarcinoma (PDAC) is to become the second leading cause of cancer-related death by 2040.

Many factors contribute to this dilemma, including lymphatic metastasis, which is the primary cause of PDAC metastasis.

The inhibition of early lymph node metastasis, including the lymphangiogenic process, may be a novel strategy for PDAC treatment.

Through miRNA sequencing of plasma extracellular vesicles (EVs) from PDAC patients, for the first time, we identified that plasma EV-miR-205-5p served as a non-invasive biomarker distinguishing lymphatic metastasis status (N0 vs.

Echo Biotech Role

Echo Biotech contributed EV isolation and purification, EV characterization, miRNA profiling/sequencing and bioinformatic analysis; the study also used or cited Exosupur®.

Related platforms: Exoomics®, Research Reagents & Tools

Related services and capabilities: Biofluid EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV miRNA Profiling / Sequencing, Research Reagent / Product Supply

Related products or reagents: Exosupur® EV Isolation/Purification Kit

References

Original publication: Extracellular vesicles-miR-205-5p inhibits lymphatic metastasis in pancreatic cancer through diffusely downregulating VEGFA Journal of Cancer. 2025. DOI: 10.7150/jca.110659. PMID/PMCID: 40302796; PMC12036096.